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Abstract  
Background 
Metastatic cancers occur when cancer cells break away from the primary tumour. One of the most 
common sites of metastasis is the bone. Several therapeutic options are currently available for 
managing bone metastases. In a resource constrained environment, policy makers and practitioners 
need to know which options are cost-effective. 
Objective 
To review and appraise published economic evaluations on treatments for the management of bone 
metastases.  
Methods  
We searched eight bibliographic databases (MEDLINE, MEDLINE in Process, EMBASE, CSDR, DARE, 
HTA, EED and CPCI) for relevant economic evaluations published from each database’s inception date 
until March 2017. Study selection, quality assessment and data extraction were carried out according 
to published guidelines.  
Results 
Twenty-four relevant economic analyses were identified. Seventeen of these studies focus on bone 
metastases resulting from a particular type of cancer (prostate (n=8), breast (n=7), lung (n=1) or renal 
(n=1)) while seven report results for various primary tumours. Across types of cancer, evidence 
suggests that bisphosphonates result in lower morbidity and improved quality of life, for an additional 
cost which is typically below conventional cost-effectiveness thresholds. While denosumab leads to 
health gains compared to zoledronic acid, it also results in substantial additional costs and it is unlikely 
to represent value for money. The limited literature on the radiopharmaceutical strontium-89 (Sr89) 
and external beam radiotherapy (EBR) suggest that these treatments are cost-effective compared to 
no treatment.  
Conclusions 
The reviewed evidence suggests that bisphosphonate treatments are cost-effective options for bone 
metastases, while denosumab is unlikely to represent value for money. Evidence on EBR and Sr89 is 
limited and less conclusive.  
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Key points for decision makers 
• Most of the identified economic literature on treatment options for bone metastases 
investigate bisphosphonates and denosumab. Evidence on the cost-effectiveness of 
radiopharmaceuticals and radiotherapy is relatively limited. 
• Studies varied in relation to perspectives adopted, inputs included and methods employed. 
This variability hinders comparisons and precludes drawing definite conclusions that could be 
applicable across health care systems.  
• In general, bisphosphonates appear to be a cost-effective option compared to placebo. 
Evidence suggests that denosumab results in improved outcomes, but its high cost makes it 
unlikely to be cost-effective. Limited evidence indicated that Sr89 and radiotherapy may be 
cost-effective options.  
 4 
 
1. Introduction  
Cancer is one of the leading causes of morbidity and mortality worldwide. An estimated 8.2 million 
people died from cancer and 14.1 million new cases of cancer occurred worldwide in 2012 [1]. 
Estimates suggest that 23.6 million new cases of cancer worldwide will be diagnosed each year by 
2030 [1]. In the UK, cancer incidence statistics indicate that 980 cases are diagnosed every day, the 
equivalent to a new cancer diagnosis every two minutes [2]. 
Cancer cells may break away from a primary cancer, enter the bloodstream or lymphatic system and 
be carried to other parts of the body where they can grow into new tumours, also known as a 
secondary cancer(s) or metastases. In patients that develop metastases, it is not the primary tumour 
but its metastases that are the main cause of death [3]. Despite developments in cancer treatments, 
a large number of patients with cancer develop metastases. One of the most common sites where 
cancer spreads is the bone. Prostate, breast, lung, renal and thyroid cancer are the most common 
cancers to metastasise to the bone [4]. No reliable incidence or prevalence figures for people with 
bone metastases are available, but it is estimated that around 70% of patients with breast or prostate 
cancer are affected by metastatic disease to the bone [5].  
Bone metastases is a debilitating condition with a detrimental impact on peoples’ quality of life (QoL). 
Bone metastases are usually associated with skeletal related events (SREs) such as severe bone pain 
(often intractable pain), an increase is susceptibility for bone fragility and consequently fracture, bone 
deformity, hypercalcaemia (increased blood-calcium concentration) and nerve-compression 
syndromes such as spinal-cord compression [6].  
Treatment options for bone metastases can often shrink or slow the growth of bone metastases and 
prevent SREs. However, treatment is predominantly palliative and is provided in order to relieve pain, 
prevent fractures, maintain activity and mobility, and, if possible, to prolong survival [7]. Therapeutic 
options for bone metastases can be divided into local and systemic. The decision on which treatment 
or combination of treatments to administer is dependent on the location and extent of the metastatic 
disease. Local treatments, which include radiotherapy, surgery and ablation techniques are directed 
at single areas of the body, either if the cancer has only spread to a single bone or an area requires 
urgent management. Systemic treatments are used in cases where the cancer has spread to several 
areas as these treatments can reach cancer cells that have spread throughout the body. Although 
contributing to the management of bone metastatic disease, systemic treatments using 
chemotherapy, endocrine therapy or immunotherapy are not aimed specifically at bone metastases. 
Radiopharmaceuticals and bisphosphonates are systemic treatments that specifically target skeletal 
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metastatic sites. Radiopharmaceuticals are agents that deliver a highly localised radiation dose to 
bone stroma [8]. These agents differ in terms of efficacy, duration of pain palliation, ability to repeat 
treatments, toxicity, and cost [9]. Commonly used radiopharmaceutical agents include strontium-89 
(Sr89), samarium-153 and radium-223. Bisphosphonates are a class of drug that reduces osteolytic 
bone lesions, the tumour burden in bone, skeletal pain and skeletal complications [6, 10]. Common 
bisphosphonates include pamidronate, clodronate and zoledronic acid (ZA). Denosumab is a newer 
and expensive human monoclonal antibody that specifically binds to and blocks activity of the 
receptor activator of NF-κB ligand (RANKL), which mediates the formation, function, and survival of 
osteoclasts [11]. It has been shown to be more effective than ZA for the prevention of skeletal-related 
events in men with bone metastases from castration-resistant prostate cancer [12]. 
Within an environment of increasingly constrained resources, it is important that treatments offered 
to the population are not only effective, but they also represent a cost-effective use of resources. We 
carried out a systematic review of existing economic evaluations to appraise the available evidence 
on treatment options for the management of bone metastases.  
2. Methods 
Methods employed throughout the review were in line with guidelines for undertaking and reporting 
systematic literature reviews in health care [13, 14].   
2.1 Study identification 
Searches for relevant economic evaluations were carried out for each of the five most common types 
of primary cancer that metastasise to the bone (prostate, breast, lung, renal and thyroid cancer) [15] 
in the following electronic bibliographic databases: MEDLINE, MEDLINE in Process and EMBASE (via 
Ovid), CSDR, DARE, HTA and EED (Wiley Cochrane) and Conference Proceedings Citation Index (Web 
of Science). Searches covered the period from each database’s inception date until March 2017.  
The employed search strategies comprised combinations of text words (e.g. synonyms, term variants) 
and index terms such as Medical Subject Heading (MeSH) terms. A search filter designed by the Centre 
for Reviews and Dissemination in York was added to locate economic evaluations [16] and an in-built 
Ovid filter was used to locate systematic reviews/HTAs for background and a possible economic 
element. The full MEDLINE search strategy can be found in the electronic supplementary material 
accompanying this article (Online Resource 1). Additional searches were carried out in the reference 
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lists of key articles and existing systematic reviews. Literature search results were uploaded to, and 
managed using EndNote X7.0.1 software. 
2.2 Study selection 
All identified articles were considered against a list of pre-specified inclusion and exclusion criteria 
(Online Resource 2). Study selection was carried out in two stages. The first stage aimed to filter out 
clearly irrelevant publications and involved applying the inclusion and exclusion criteria on each 
article’s title and abstract. Publications that met the inclusion criteria, as well as articles for which an 
exclusion or inclusion decision could not be made based on their title and abstract alone, were 
forwarded to the second stage, where they were judged on the basis of their full text. 
For each of the five types of cancer, selection of articles was carried out independently by two of the 
three reviewers (LA, RD, IG). Disagreement was addressed through discussion and, if necessary, 
through consulting a third reviewer. 
2.3 Data extraction and quality assessment  
A customised form was created to extract relevant data. Such data included bibliographic information 
(author(s), journal and year of publication), general information (country, population, interventions 
and comparators), methodological characteristics (type of economic evaluation, analytic method 
employed, perspective, discounting, key cost categories, key outcomes) and findings (main results and 
authors’ conclusions). 
Quality assessment was carried out using the Consensus on Health Economic Criteria (CHEC-list) 
checklist [17], which is recommended for appraising the methodological quality of economic 
evaluations [14]. The list comprises 19 items, each of which represents a question which was answered 
by ‘yes’, ‘no’, ‘unclear’ or ‘not applicable’. Negative answers to the CHEC-list do not necessarily 
indicate poor practice or result in bias. While no identified studies were discarded on the grounds of 
poor quality, limitations were noted and discussed in subsequent sections.  
The identified studies were split into three sets, with each set being assigned to two of three reviewers 
(set A: IG and RD; set B: LA and IG; set C: RD and LA). Each of the assigned reviewers performed data 
extraction and quality assessment independently. Disagreements were resolved through discussion 
between reviewers and, when necessary, by seeking the opinion of a third reviewer. A further round 
of accuracy checks was carried out on all data extraction forms by LA. Narrative synthesis was used to 
interpret, summarise and present the information provided in the selected articles. Results are 
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reported in line with good practice recommendations for narrative summaries of health economic 
studies as outlined in the Cochrane Handbook for Systematic Reviews [14].  
3. Results 
A PRISMA diagram showing the key stages of the selection process is provided in Figure 1. A total of 
3479 records were retrieved. Of these 3467 records were found through searches in bibliographic 
databases and 12 were identified through supplementary searches. Removal of duplicate records 
resulted in 2495 unique articles. Title and abstract screening of these articles led to the exclusion of 
2414 citations, leaving 81 potentially relevant articles to be considered for inclusion. Full text 
assessment of the 81 potentially relevant studies resulted in the exclusion of a further 57 references. 
The remaining 24 references [18-41] formed the final set of reviewed studies.  
3.1 Overview of included studies 
Seventeen of the 24 identified studies [18-21, 23-25, 28-33, 35, 36, 39, 40] are concerned with bone 
metastases resulting from a particular type of primary cancer (Figure 2). Of these, eight studies focus 
on prostate cancer [18, 21, 29, 31-33, 36, 40], seven studies on breast cancer [19, 23-25, 28, 35, 39], 
one study on lung cancer [30] and one study on renal cancer [20]. Seven studies [22, 26, 27, 34, 37, 
38, 41] report results drawn from groups involving patients with various tumours (e.g. breast, cancer, 
lung and other solid tumours); of these, five present results separately by type of cancer [22, 26, 34, 
37, 41] and two studies report combined findings across different types of cancer [27, 38]. No 
economic evaluations on treatment options for bone metastases secondary to thyroid cancer were 
identified.  
Figure 3 shows the number of identified articles by year of publication. With the exception of two 
studies [25, 32], all of the identified economic evaluations were published after 2000. Nearly half of 
those studies were published within five years, between 2010 and 2014 [20, 21, 26, 30, 35-37, 39-41].   
Twenty of the identified studies [18, 19, 22-29, 31, 32, 34-41] focus on a single country, while four 
studies report results for more than one country [20, 21, 30, 33]. Of the studies focusing on a single 
country, ten were conducted in Europe (seven in the UK [18, 19, 23, 24, 26, 29, 34] and one in each of 
Greece [41], the Netherlands [38] and Switzerland [27]), nine in North America (seven in the United 
States [28, 31, 35-37, 39, 40], two in Canada [25, 32]) and one in New Zealand [22]. Among studies 
reporting results for more than one country, three [20, 21, 30] had a focus on a small number of 
European countries, while one study pooled information from 17 countries, including Argentina, 
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Australia, Brazil, Italy and Sweden [33]. In total, the reviewed literature pertained to 20 different 
countries.  
A summary of key characteristics of the identified studies, including the compared interventions, 
employed methodology and main findings are given in Tables 1 and 2. Sixteen of the identified studies 
were CUAs, reporting outcomes in terms of quality-adjusted life years (QALYs) [18-26, 29-31, 35, 36, 
38, 41], while four [32, 34, 39, 40] were CEAs reporting outcomes such as instances of SREs prevented. 
Three studies [28, 33, 37] conducted both CUA and CEA analyses and one performed a CCA [27], with 
costs and outcomes being presented in a disaggregated form.  
In relation to the analytic approach adopted, 18 of the identified evaluations [19-26, 28, 30, 31, 34-
37, 39-41] involved synthesising information from various sources (e.g. evidence published in the 
literature, estimates drawn from patient-level data, expert opinion and other secondary sources) 
through some form of a decision analytic structure. The remaining six studies [18, 27, 29, 32, 33, 38] 
involved using statistical methods to analyse patient-level data collected from a single clinical trial 
(most often randomised clinical trials (RCTs)).  
The perspective of the analyses, that is, the viewpoint from which costs and benefits were calculated, 
varied across studies. Half of the studies [18-20, 22-26, 29, 30, 34, 41] reported results from the 
perspective of the health care system in the countries they relate to, with eight studies [21, 27, 31, 
35-37, 39, 40] adopting a third-party payer perspective, under which costs and consequences were 
included if they were deemed relevant to the entity covering the cost of the provided care. A societal 
perspective, which is meant to encompass all costs and consequences accruing across the society, was 
stated as the adopted viewpoint in three studies [28, 33, 38], while one study did not report the 
perspective of the presented analysis [32]. 
The time frame over which results were calculated varied across studies. A time horizon that is long 
enough to capture all the costs and benefits is typically recommended [42, 43] though, in the reviewed 
studies, this was often dictated by the follow-up period in clinical studies which provided data for the 
economic evaluations. One study reported results over time horizon shorter than 12 months [27], 
eight studies [19-21, 23, 24, 33, 39, 40] looked at costs and benefits accruing between 12 and 24 
months, eight studies reported results over time horizons equal to or longer than 24 months [18, 19, 
28, 29, 31, 34-36], while four studies [22, 30, 32, 37] produced results over a lifetime horizon. One 
study analysed costs and benefits accruing over different lengths of time [38], while in another study, 
by Yfantopoulos and colleagues [41], the length of time horizon varied according to the type of primary 
cancer investigated.  
 9 
 
Consistently with recommendations [44, 45], discounting was carried out to account for positive time 
preference in 11 studies [18-20, 22, 26, 29, 34-38] which had time horizons greater than 12 months. 
Discounting was not performed in 9 studies reporting results over time horizons greater than 12 
months [21, 23, 24, 28, 30-33, 41]. 
As expected, costs included in the analyses depended largely on the adopted perspective. Typically, 
the list of included cost categories comprised treatment-related costs (i.e. the acquisition and 
administration cost of the bone protecting treatments) and costs due to hospital care provided in 
response to skeletal problems (e.g. outpatient appointments, hospitalisation for skeletal related 
events). In eight studies [18, 19, 22, 28, 29, 33, 34, 38], costs extended to use of primary and 
community care services. Figure 4 shows the split between studies in terms of key outcomes reported. 
CEAs commonly adopted the outcome of avoided SREs. An SRE is typically defined as the occurrence 
of a pathologic fracture or spinal cord compression, or the need for radiation therapy or surgery to 
bone. In CUAs, outcomes were invariably reported in QALYs, a composite measure that incorporates 
time spent in a particular state of health and preference-based QoL associated with this state.  
Indications on the methodological quality of the identified studies were obtained through assessment 
against the 19 items (questions) of the CHEC-list quality assessment checklist [16]. Answers to CHEC-
list questions are given in Table 3. Positive answers to these questions are considered to be indicative 
of good practice in undertaking and reporting economic evaluations. In all of the identified studies, 
the number of positive (‘yes’) answers exceeded those of negative (‘no’) or other answers (‘unclear’ 
or ‘not applicable’). Many of the negative responses were given to items 17, 18 and 19 of the CHEC-
list, which relate to the generalisability of the study results, a discussion of the ethical and 
distributional issues associated with findings, and the indication of potential conflict of interest.  
3.2 Findings of identified studies 
Key characteristics and findings of the identified studies are presented below according to type of 
primary cancer.  
3.2.1 Prostate cancer 
Articles assessing the cost-effectiveness of treatments for bone metastases due to prostate cancer 
comprised the largest group of the identified studies. Treatments assessed included the radioisotope 
strontium-89 (Sr89), various bisphosphonates (most commonly ZA, but also pamidronate, ibadronate 
and clodronate), denosumab, as well as single and multiple fraction external beam radiotherapy.   
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In the earliest of the identified studies, McEwan et al. [32] assessed the cost-effectiveness of Sr89, a 
local treatment which settles to the site of bone metastases and delivers radiation, as a palliative 
option for bone-metastatic prostate cancer. The authors sought to establish the difference in costs 
and outcomes resulting from treatment with Sr89 (Metastron®) as compared to placebo. In doing so, 
McEwan et al. [32] analysed data retrieved from hospital records and case report forms collected as 
part of the Trans Canada trial of Metastron®. The authors found that the total per-patient cost of 
care—which included the cost of drugs, radiotherapy, investigations and stay in a tertiary unit—was 
lower for those who received Sr89, resulting in a total cost saving of CAN $209 per week of survival as 
compared to patients who received placebo. However, the authors noted that their calculations of the 
total cost of care did not include general practitioner visits and, crucially, the cost of Sr89 or the initial 
radiotherapy.  
Sr89 for patients with prostatic bone metastases was also assessed in a study reported by James et al. 
[29] and Andronis et al. [18]. The authors analysed patient-level resource use and outcome data 
collected alongside the TRAPEZE factorial RCT [46], which was funded by the National Institute for 
Health Research Health Technology Assessment programme in the UK to compare Sr89 in addition to 
standard chemotherapy against no Sr89. The analysis, which was conducted from the perspective of 
the UK health care system, found that the addition of Sr89 to standard chemotherapy led to a small 
increase in costs (mainly due to radioisotope acquisition and administration costs) and a modest 
improvement in QoL, resulting in an additional cost of £17,000 per QALY gained as compared to no 
Sr89 treatment.   
Data from the TRAPEZE trial were also used to evaluate the cost-effectiveness of ZA, a drug that aims 
to prevent loss of bone mass, as compared to no ZA. In the analysis reported by James et al. [29] and 
Andronis et al. [18] the authors found that the extra acquisition and administration cost for ZA was 
almost compensated by savings due to fewer SREs, resulting in a small additional cost (or an overall 
cost saving, depending on the acquisition cost of ZA) for a small improvement in QALYs. The additional 
cost for providing proprietary ZA alongside standard chemotherapy treatment was found to be £8000 
per QALY gained; however, additional analyses carried out to reflect the availability of generic, 
inexpensive ZA showed this option to dominate its comparator, resulting in a lower total cost and a 
modestly higher number of QALYs.    
ZA in addition to standard chemotherapy was also the subject of the studies by Reed et al. [33] and 
Carter et al. [21]. Reed et al. [33] analysed evidence collected alongside a multinational RCT to 
compare ZA against placebo in terms of the additional cost per SRE avoided, additional cost per patient 
free of SRE and additional cost per QALY. Findings showed ZA to be associated with an additional cost 
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of US $12,300 per SRE avoided, US $51,400 per patient free of SRE and US $159,200 per QALY gained. 
While ZA appeared to result in improved outcomes, the authors concluded that the estimated 
incremental cost is higher than cited values below which treatments are typically considered cost-
effective. 
In an analysis carried out from the perspective of payers in France, Spain, Portugal and the 
Netherlands, Carter et al. [21] synthesised costs drawn from published sources and clinical evidence 
obtained from an RCT to establish the cost-effectiveness of ZA in each of the four countries. Findings 
showed that patients who received ZA experienced fewer SREs and, as a result, a lower cost of SRE 
complications. However, the addition of ZA resulted in further acquisition and administration costs 
which led to overall higher total costs, ranging from €87 in the Netherlands to €1284 in France. 
Combining the total costs with a calculated increase in QALYs by 0.036 led to ICERs ranging from 
approximately €2,400 to €36,000 for the Netherlands and France, respectively. 
The cost-effectiveness of denosumab, a newer pharmaceutical which prevents the development of 
osteoclasts, was assessed in five economic evaluations [26, 36, 37, 40, 41]. All of these studies 
employed decision analytic models to compare denosumab against ZA, the most widely-used 
bisphosphonate in bone-metastatic prostate cancer.  
In the earliest of the identified studies on denosumab, Xie et al. [40] drew clinical data from a Phase 
III RCT and used a nine-state Markov model to calculate the incremental cost per SRE avoided over 
one-year and three-year time horizons. Results showed denosumab to be associated with higher total 
costs and fewer SREs, resulting in additional costs of US $71,027 and US $51,319 per SRE avoided over 
one year and three years, respectively.  
Stopeck et al. [37] looked at the value of denosumab for the prevention of SREs in four bone-
metastatic solid tumours, including prostate, breast and lung cancer, from a payer’s perspective in the 
US. The analysis was based on a Markov model with a lifetime horizon and made use of SRE reduction 
rates from three RCTs. With regards to prostate cancer, the authors [37] found denosumab to be 
associated with additional costs of US $49,405 and US $8567 per QALY gained and SRE avoided, 
respectively. While Stopeck and colleagues [37] concluded that denosumab is a cost-effective 
treatment option, largely due to its superior efficacy in preventing SREs, they acknowledged that 
results are sensitive to the cost of drugs and, importantly, the employed rate of SRE occurrence.  
Similarly, Yfantopoulos et al. [41] conducted a model-based analysis to assess the cost-effectiveness 
of denosumab compared to ZA in preventing SREs due to bone metastases from solid tumours, 
including prostate cancer. The analysis, which was carried out from a payer’s perspective in Greece, 
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used a spreadsheet model which was populated by data drawn from the literature and health care 
records. The main analysis, which assumed that denosumab will be covered by a recently established 
overarching health insurance provider in Greece (EOPYY), indicated an additional cost of €61,296 per 
QALY gained and €4,889 per SRE avoided, respectively, leading the authors to conclude that 
denosumab is not a cost-effective alternative to ZA for prostatic bone metastases, assuming that 
society (or decision makers) in Greece would be willing to pay up to €30,000 for an additional QALY. 
The authors found that a reduction of the cost of denosumab by €15-€20 can make the treatment 
appear cost-effective, which is indicative of the uncertainty associated with the study findings. This 
uncertainty was not presented in the study, which relied on effectiveness data and model structure 
presented in another non-peer reviewed paper (conference abstract). 
Ford et al. [26] compared denosumab against ZA by re-building and updating a model submitted to 
the National Institute of Health Care Excellence (NICE) Multiple Technology Appraisal programme in 
the UK. The analysis assessed the cost and QALYs for breast, prostate, lung and other solid tumour 
cancers through Markov model based on 4-week cycles over a 10-year time horizon. Results specific 
to prostate cancer showed that the cost-effectiveness of denosumab is contingent on the treatment’s 
cost and, therefore, on access to a patient access scheme (PAS)—a provision that involves a pricing 
agreement between a drug manufacturer and the NHS. Without PAS, denosumab for prostate cancer 
was associated with a high cost per QALY value of £111,603 and it was not deemed cost-effective 
compared to ZA. With PAS, denosumab dominated ZA, being less costly and more effective (in terms 
of QALYs). The authors noted that, owing to small gains in QALYs estimated in the analysis, the cost-
effectiveness of denosumab was highly sensitive to the price of ZA.  
In the same year, Snedecor et al. [36] developed an eight-state Markov model and populated it with 
data from the literature to calculate costs and effects (SREs avoided and QALYs) over a 27-month time 
horizon. The analysis showed denosumab to result in fewer SREs but higher total costs. The additional 
costs, in the order of US $7841, and the modest gain of 0.007 QALYs due to fewer SREs resulted in a 
cost per QALY gained value in excess of US $1 million. The authors attribute the fact that this figure is 
much higher than those in the analyses by Stopeck et al. [37] and Ford et al. [26] to differences in the 
calculations of three key parameters: drug-associated costs, SREs avoided and QALYs gained. 
Two studies [22, 31, 38] looked into the cost-effectiveness of different schedules of external beam 
radiotherapy (EBR) for bone-metastatic prostate cancer. EBR is a palliative therapy for relieving local 
metastatic bone pain which can be administered in single or multiple fractions. 
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Single versus multiple-fraction EBR was evaluated in an analysis carried out by Konski [31] from a 
payer’s perspective in the US. In this study, the author developed a Markov model to evaluate various 
palliative treatments for bone metastases from prostate cancer, including systemic chemotherapy 
(mitoxantrone plus prednisone), two radiotherapy schedules and best supportive care (pain 
medications only). Key model inputs on transition probabilities, costs and preference-based QoL were 
obtained from published sources and expert opinion. The analysis showed that, compared to best 
supportive care, single-fraction and multi-fraction EBR resulted in an additional cost of US $6857 and 
US $36,000 per QALY gained, respectively, while chemotherapy was dominated by the rest of the 
options. While a comparison between single-fraction and multiple-fraction EBR is not reported, cost 
and QALY values for these two options presented in the paper result in an ICER of US $8667 per QALY 
gained for multiple-fraction EBR compared to single-fraction EBR. 
In a more recent study carried in New Zealand, Collinson et al. [22] built a Markov model to evaluate 
the costs and QALYs associated with single and multiple-fraction EBR for metastatic bone pain in 
prostate, breast and lung cancer. The model synthesised data from a range of sources, including RCTs 
and routine data collected in New Zealand. QALYs were calculated using disability weights from the 
Global Burden of Disease study, rather than index values from multi-attribute utility systems (such as 
the EQ-5D). In relation to prostate cancer, model output showed single-fraction EBR to be associated 
with lower costs and a slightly greater number of QALYs compared to multiple-fraction EBR, which led 
the authors to conclude than single-fraction EBR is a superior option.    
3.2.2 Breast cancer 
Eleven articles assessing the cost-effectiveness of treatments for bone metastases due to breast 
cancer were identified [19, 23-26, 28, 34, 35, 37, 39, 41], of which four [26, 34, 37, 41] present results 
for breast cancer alongside other solid tumours. Treatments assessed included various 
bisphosphonates, denosumab, as well as single and multiple fraction radiotherapy. 
The cost-effectiveness of bisphosphonates in bone metastases secondary to breast cancer was 
evaluated in six studies. Based on clinical evidence suggesting that pamidronate taken once a month 
reduces the incidence of SRE in breast cancer patients, Dranitsaris and Hsu [25] carried out a CUA to 
compare this bisphosphonate against placebo. The analysis, which was conducted through a simple 
decision analytic model, combined three key sources of information: rates of SRE occurrence taken 
from a clinical trial, drug and hospital care related costs found in routine hospital source, and QoL 
weights derived from a small sample of health professionals and breast cancer patients. Findings 
showed pamidronate to be more costly and more effective than placebo, resulting in an additional 
cost of CAN $18,700 per additional QALY gained.   
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An evaluation of the cost-effectiveness of pamidronate compared to placebo was also pursued in a 
model-based analysis carried out in the US by Hillner et al. [28]. The authors combined results on 
incidence of SREs from two RCTs, resource use categories and costs from routine sources and QoL 
weights elicited from experts to calculate incremental costs per SRE prevented and QALYs gained over 
a two-year period. Findings suggested that the cost of adding pamidronate to existing treatment 
regimens (hormonal systemic therapy or chemotherapy) exceeded the savings from reduced 
occurrence of SREs, resulting in additional cost per QALY values of US $108,200 and US $305,300 for 
chemotherapy and hormonal therapy, respectively.   
A wider range of bisphosphonates—including ZA, pamidronate, chlodronate and ibadronate—were 
evaluated in three studies [19, 23, 24, 34]. Botteman and colleagues [19] built a decision model to 
compare five commonly-used bisphosphonates (oral and intravenous ibandronate, ZA, generic 
pamidronate and generic oral clodronate) against placebo. The analysis was carried out from the 
perspective of the UK health care system. Model inputs, including treatment costs, SRE costs and 
preference-based QoL indices were obtained from the literature. The authors reported that ZA and 
oral ibadronate resulted in cost savings, pamidronate and intravenous ibadronate led to additional 
costs, while patients on all bisphosphonate therapies experienced, on average, fewer SREs and 
improved quality-adjusted life expectancy. Reported findings indicate that offering bisphosphonate 
treatment is a cost-effective option compared to placebo. All bisphosphonates resulted in incremental 
cost per QALY values less than or equal to £2,400 compared with placebo, with ZA being the dominant 
bisphosphonate.   
The cost-effectiveness of oral ibadronate was also investigated in two studies published in 2005 by De 
Cock and colleagues [23, 24]. The first study [23] aimed to compare oral ibadronate against 
intravenous pamidronate or ZA in breast cancer patients receiving hormonal therapy. For this 
purpose, the authors adapted a global economic model to the UK health care system. The model 
extrapolated costs and outcomes over a lifetime horizon by combining data on resource use and QoL 
with incidence of SREs. Model results suggested oral ibadronate to be more effective and less costly 
than ZA or intravenous ibadronate. However, the authors acknowledge that results would only hold 
true given certain assumptions (e.g. differences in QALYs are driven only by QoL, not survival), while 
the absence of efficacy data from head-to-head comparisons of the assessed bisphosphonates is a 
limiting factor. The second study by De Cock and colleagues [24], which shared much of the structure 
and inputs of the first study, compared oral ibandronate against intravenous ZA and generic 
intravenous pamidronate in patients undergoing chemotherapy. In this study, too, oral ibadronate 
was found to be less costly and more effective than its counterparts, making it the dominant option.  
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ZA was compared against other bisphosphonates and no ZA as options for the prevention of skeletal 
morbidity and hypercalcaemia in an economic evaluation conducted by Ross et al. [34]. The authors 
carried out a systematic review of existing studies and they used the retrieved information as input in 
a decision analytic model. The analysis focused on metastases secondary to either breast cancer or 
multiple myeloma, on the basis of a four-year time horizon from the perspective of the health care 
system in the UK. Results were presented in the form of cost per duration of normocalcaemia (i.e. 
normal concentration of calcium in the blood) and cost per SRE prevented. A wealth of results was 
presented depending on the source of the input data. The authors concluded that ZA (8mg dose) was 
the most cost-effective option for hypercalcaemia and bisphosphonate therapy represented value-
for-money in preventing SREs, with incremental costs ranging from £250 to £1500 per event avoided. 
The emergence of denosumab as an effective alternative to bisphosphonate treatment for patients 
suffering from bone metastases has given rise to studies evaluating the agent’s cost-effectiveness, 
typically in comparison to ZA [35, 39]. Xie et al.[39] investigated the additional costs and benefits of 
denosumab in breast cancer patients from the perspective of a third-party payer in the US. In doing 
so, the authors built an 11-state Markov model and calculated outcomes over a 1-year time horizon. 
Clinical inputs in the model (e.g. incidence of SREs at different times) were derived from a large Phase 
III clinical trial comparing denosumab and ZA [47], while cost inputs (treatment-related costs and 
resource use due to SREs and adverse events) were obtained from various sources, including a claims 
dataset and available trial evidence. Denosumab was found to be more costly but more effective (in 
terms of number of SREs avoided in 1 year), resulting in an incremental cost of US $114,628 per SRE 
avoided. The same options were investigated in a study by Snedecor et al.[35]. Similarly to Xie et al., 
Snedecor and colleagues [35] built a Markov model to calculate costs and outcomes (avoided SREs 
and QALYs) associated with denosumab and ZA from a payer’s perspective in the US. In their base-
case analysis, the authors run the model over a 27-month period (60 months in sensitivity analysis), 
which reflected the timeframe for which patient-level data were available. Clinical, cost and QoL 
inputs were largely drawn from the available literature. Base-case results suggested that denosumab 
is associated with a significantly higher cost than ZA (largely due to drug-related costs) and a greater 
number of QALYs (due to a lower incidence of SREs), resulting in an overall incremental cost per QALY 
gained value of US $697,499 and prompting the authors to question the economic value of the drug.  
Comparisons of denosumab and ZA are also reported in three of the studies looking into treatments 
for bone metastases secondary to various solid tumours, rather than only breast cancer [26, 37, 41]. 
A description of the methods used in these studies can be found under the prostate cancer heading 
above. In relation to breast cancer, Stopeck et al.[37] found denosumab to result in an additional cost 
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per QALY gained of US $78,915, Yfantopoulos et al. [41] reported a value of €56,818 per QALY gained 
for the same comparison, while Ford et al. [26] found denosumab to be associated with a high cost 
per QALY value of at least £190,841 depending on the assumptions employed. Calculations on the 
basis of access to a PAS resulted in denosumab dominating ZA, being less costly and more effective (in 
terms of QALYs). 
3.2.3 Lung cancer 
Five studies reported economic evaluations of treatments for patients with bone metastases due to 
lung cancer. Of these, the study by Joshi et al. [30] focused on lung cancer only, while the remaining 
studies investigated lung cancer alongside other conditions [22, 26, 37, 41].  
Joshi and colleagues [30] carried out an economic evaluation to assess the cost-effectiveness of ZA 
compared to placebo in patients with non-small cell lung cancer (NSCLC) in five European countries 
(France, Germany, UK, Portugal and the Netherlands). The analysis, which has the form of a model-
based CUA, made use of data from various sources. Estimates of survival and SRE incidence were 
calculated on the basis of data from a large RCT [48, 49], resource use and costs were taken from the 
literature and routinely collected hospital data, while QoL was estimated according to values 
published in the literature. In their base-case analysis, the authors found ZA to be associated with 
fewer SREs, more QALYs and cost savings or a modest increase in costs, depending on the country. 
Overall, ZA appeared to be less costly and more effective than placebo in Germany, UK and Portugal, 
and resulted in incremental cost per QALY gained values of €786 and €8278 in France and the 
Netherlands, respectively.   
The rest of the studies [22, 26, 37, 41] presenting results for lung cancer did so alongside findings for 
other types of primary cancers. A fuller description of this work has been given above, under other 
headings. Three of these studies compared denosumab with ZA [26, 37, 41]. Stopeck et al. [37] found 
that denosumab is more costly and more effective than ZA in lung cancer patients with bone 
metastases, resulting in an incremental cost per QALY gained value of US $67,931. Yfantopoulos et al. 
[41] found that denosumab would cost the country’s social insurance funds an additional €80,830 per 
QALY gained as compared to ZA for patients with solid tumour metastases secondary to cancers other 
than breast or prostate. In an analysis carried out from the viewpoint of the health care system in the 
UK, Ford et al. [26] calculated an incremental cost per QALY of £12,743 provided that denosumab is 
reimbursed through a PAS and £110,671 in the absence of the scheme. Lastly, Collinson et al.  [22], 
evaluated delivery schedules for EBR and found that, from the viewpoint of the health care system in 
New Zealand, single-fraction EBR is less costly and more effective (in QALYs) than multiple-fraction 
EBR. 
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3.2.4 Renal cancer 
Only one economic evaluation with a focus on bone metastases secondary to renal cancer was 
identified. In this study, Botteman et al. [20] set out to assess the cost-effectiveness of ZA against 
placebo in patients with renal cancer in three countries: France, Germany and the UK. The purposes 
of the study were pursued through a simple decision analytic model which combined patient-level 
data from an RCT funded by the manufacturer of ZA, assumptions and information from the literature.  
The authors found ZA to be the dominant option, being associated with lower costs and a gain in 
QALYs in all three countries.   
3.2.5 Studies reporting combined results for various types of primary cancers  
Two studies [27, 38] presented results which were combined across different types of cancer.  Van 
den Hout et al. [38] carried out a CUA to compare a single-fraction against a multiple-fraction (six 
fractions) schedule in patients with various solid tumours (breast, lung, prostate and other types of 
cancer). The analysis, which included costs accruing to the Dutch health care system and the patient, 
drew on data collected alongside a Dutch RCT. Results were presented as cost per quality-adjusted life 
expectancy and cost per QALY for all patients, rather than by type of primary cancer. The study showed 
single fraction radiotherapy to be less costly and more effective (in terms of quality-adjusted life 
expectancy), however none of the reported differences were statistically significant. It is worth noting 
that the latter results relate to a comparison of total societal cost over 12 weeks and QALYs over 2 
years. The authors justify this difference in measurement periods on the ground that no statistically 
significant differences in costs were observed after the period of 12 weeks.  
Similarly, Gessner et al. [27] evaluated two dosage regimens of pamidronate, a second-generation 
bisphosphonate, in an analysis carried out on the basis of data from 70 trial participants suffering from 
different types of advanced cancer (breast cancer, multiple myeloma and other tumours). The total 
cost (ECU 12,060) comprised treatment-related, inpatient and outpatient costs and was presented for 
all patients (i.e. irrespective of type of primary cancer) and for both treatments combined.  In relation 
to outcomes, the authors found the 60mg dose of pamidronate to lead to a 36% reduction in pain 
intensity compared to baseline, while the 90mg dose led to a smaller reduction, by 15%. The authors 
concluded that treatment with pamidronate resulted in a significant reduction in pain, but did not add 
noticeably to the costs.   
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4. Discussion 
Bone metastasis is a frequent and highly debilitating complication of cancer with important economic 
consequences. We reviewed existing economic evaluations to summarise the available evidence on 
the economic value of treatment options for the management of bone metastases. The review 
identified 24 economic evaluations assessing treatments in patients with different primary cancers. 
Such treatments include i) the radioisotope Sr89 (compared against no treatment), ii) single and 
multiple fraction EBR (compared with each other and against no EBR) iii) bisphosphonates (most often 
ZA, compared against placebo or other bisphosphonates) and iv) denosumab (invariably compared 
against ZA).  
4.1 Key findings 
While the diversity in the inputs and evaluation methods used across the identified studies calls for 
caution in drawing definitive conclusions, the review offers useful insights into the cost-effectiveness 
of treatment options for bone metastases.  
Much of the reviewed economic evaluation literature on bone metastases due to prostate cancer 
focuses on bone-targeted therapies such as denosumab and bisphosphonates, most commonly ZA. In 
general, evidence suggests that ZA leads to fewer SREs and a greater number of QALYs, but it also 
results in higher costs, the magnitude of which appears to be contingent on the acquisition cost of ZA. 
Denosumab, a newer alternative to bisphosphonates, was invariably found to be marginally more 
effective than ZA in preventing SREs and improving patients’ QoL. Nonetheless, findings suggest that 
superior effectiveness comes at a considerable additional cost; while this cost varies across studies 
and countries, there is an agreement between authors that, in the absence of special arrangements 
such as PAS, denosumab is unlikely to represent ‘value for money’. A small number of the reviewed 
studies assessed the value of radiation therapies and radiopharmaceuticals in prostatic bone 
metastases. In general, findings suggest that Sr89 is likely to result in improved outcomes for a 
relatively modest increase in costs (or even cost savings) compared to no Sr89 treatment. However, 
results on the cost-effectiveness of different delivery schedules of EBR are less conclusive, with the 
limited identified literature suggesting that either single-fraction EBR or multiple-fraction EBR may be 
superior.  
In breast cancer, evidence suggests that bisphosphonate treatments are more effective in improving 
QoL and reducing the occurrence of SREs when compared to placebo. While such treatments are also 
more costly, the estimated additional cost per QALY gained values are typically lower than commonly 
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cited cost-effectiveness thresholds. Similarly to findings in patients with prostate cancer, denosumab 
is shown to be more effective but considerably more costly than ZA, with the lowest incremental costs 
per QALY value reported being in excess of €57,000 [41]. Denosumab dominated ZA—being less costly 
and more effective—only when access to PAS was considered [26]. 
With regards to lung cancer, findings suggest that, in comparison to placebo, ZA leads to QALY gains 
at an additional cost that is relatively low. In line with findings for breast and prostate cancer, 
denosumab is seen to be more effective but substantially more costly than ZA, resulting in incremental 
cost per QALY values greater than $68,000 [37], unless a PAS arrangement is in place. Single-fraction 
EBR is shown to result in cost savings and gains in QALYs compared to multiple-fraction EBR, thought 
these findings come from a single study. Last, in the only economic study on bone metastases for renal 
cancer, evidence suggests that ZA would result in gains in QALYs for a modest additional cost (or cost 
savings in some countries).  
In summary, across types of cancer, the reviewed evidence suggests that offering bisphosphonates 
such as pamidronate, ibadronate and ZA to patients with bone metastases results in lower SRE 
incidence and additional QALYs achieved at costs below conventional thresholds. While denosumab, 
an alternative to bisphosphonate treatment, leads to small health gains compared to ZA, it also results 
in substantial additional costs and it is unlikely to represent ‘value for money’. The limited evidence 
on radiopharmaceuticals suggest that Sr89 is a cost-effective option. While external beam 
radiotherapy is shown to be cost-effective for patients with localised bone metastases, the evidence 
on the economic superiority of multi-fraction over single fraction EBR is inconclusive.   
4.2 Methodological issues and comparability 
As noted above, combining the findings of the 24 identified studies into conclusive statements is 
hindered by a number of factors. First, notable diversity stems from the fact that identified studies 
relate to a variety of countries. While, from a clinical perspective, the effectiveness of compared 
treatments can be assumed to be generalisable across countries, comparisons of cost-effectiveness 
results need to be exercised with caution, given the considerable variability in the structure of health 
care systems, differences in the delivery and cost of health care services, and diversity in patient access 
schemes and reimbursement mechanisms available in different countries [26, 41].  
Secondly, considerable variability arises from the fact that studies report analyses from different 
perspectives, including those of a third-party payer (e.g. Medicaid in the US), health care systems (e.g. 
the NHS in the UK) or the society. Inevitably, costs and benefits that are included in studies conducted 
from a particular perspective (e.g. societal) may have been left out from analyses adopting other 
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perspectives. Similarly, differences in the unit cost of care and price of pharmaceuticals across 
jurisdictions makes drawing conclusions on the basis of reported cost and benefit figures haphazard. 
Thirdly, there is variation in the interpretation of results, which is particularly prominent in the 
common situation when a treatment is overall more effective but also more costly. This variation is 
directly linked to uncertainty around what constitutes the maximum amount that decision makers in 
different jurisdictions should be willing to pay for a unit of outcome. Various WTP values are used as 
thresholds for judging cost-effectiveness across the 24 studies. For example, Yfantopoulos et al. [41] 
assumes a threshold of €30,000 per QALY in Greece, which they justify on grounds of the country’s 
recent economic downturn, while Collinson et al. [22] use a value of NZ $45,000 based on WHO’s 
suggestions that links WTP for a QALY with a country’s gross domestic product. However, WTP values 
for a unit of benefit vary across jurisdictions, depending on various socioeconomic factors and 
characteristics of health care systems [50]. Thus, ambiguity around an acceptable WTP is exacerbated 
by the paucity of specific guidance about acceptable WTP values in particular countries, including the 
US [51]. While in this review we have endeavoured to present authors’ conclusions as closely as 
possible, to facilitate judgements on what may be perceived to be cost-effective when a WTP value 
was not mentioned we based such judgements on indicative values of WTP for an additional QALY 
suggested by NICE in the UK [43].  
The review gave rise to a number of observations related to the methods used in the identified 
literature. Across studies, the reviewed evidence suggested that a large part of the total incremental 
costs is due to the acquisition cost of treatments. As the identified studies span a 23-year period (with 
11 of them being published before 2007) one should bear in mind that drug acquisition prices, as well 
as other health care related costs, are subject to change. This can be seen in studies assessing ZA in 
the UK: while early studies [33, 34] used a British National Formulary (BNF) unit cost of £195 per dose 
of ZA (2004 prices), later studies, making use of more recent versions of BNF employed lower prices 
per dose in their calculations (£174 in Ford et al. [26] and £155 in Andronis et al. [18]). More 
importantly, the degree to which robust inference can be made on the basis of early studies is 
influenced by changes in the price of treatments due to patent expiration and emergence of generic 
alternatives. Such is the case with ZA (Zometa®), which lost patent protection in 2013. While much of 
the identified literature suggests that offering ZA results in greater overall costs than not offering the 
treatment, more recent analyses carried out on the basis of inexpensive non-proprietary ZA report a 
high likelihood that this treatment may actually result in cost savings [18, 29]. Additionally, although 
it is sensible to expect that a share of the burden of caring for a patient who developed an SRE, 
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especially a pathological fracture, may fall to the patient’s informal carers, costs reflecting this burden 
have not been included in most of the identified analyses.  
The review also raised a number of points in relation to outcomes. The most commonly used measure 
in identified CEAs was instances of SREs avoided. Indeed, this is a sensible choice of a ‘natural’ 
outcome which captures a key intended goal of bone metastatic treatment. However, measuring 
outcomes in such natural units is less useful for informing decisions aiming to allocate resources across 
different disease groups or health care programmes [52]. Such decisions are facilitated by using 
outcomes such as QALYs, which were the measure of health benefit in all of the reviewed CUAs. QALYs 
take into account both the length of time spent in a particular state and the preference-based QoL 
associated with this state. Despite these advantages, the use of QALYs in the identified studies poses 
some limitations. Firstly, there are variations across studies in the methods used to derive preferences 
for health care states. Secondly, there are concerns that QALYs generated from generic measures may 
not be appropriately sensitive to reflect changes in cancer [53, 54]. Thirdly, while end-of-life may be 
an important consideration, there were no indications that this was taken into account across the 
reviewed studies [37, 38]. Last, in cases where preference-based QoL scores have not been obtained 
at points in time when individuals suffered from SREs, impairments in QoL are unlikely to have been 
captured in patient-level data [18]. Thus, to incorporate these decrement in their analyses, 
researchers have unavoidably resorted to making assumption about the magnitude and duration of 
the effect, with the later varying from one month [20, 28, 30] to one year [25].  
An additional point relates to authors’ normative assumptions of what cost or outcome-related 
parameters to include in analyses. For example, Snedecor and colleagues [36] did not consider disease 
progression and adverse events in their analysis on the basis that these were not significantly different 
between treatment comparators. It is important that key assumptions are comprehensively tested in 
sensitivity analyses and that the uncertainty associated with key study findings is reported clearly. This 
will help explore the robustness of the study findings to variations in key assumptions and analytical 
methods used and will allow more definitive conclusions to be drawn, particularly in a context where 
most of the identified studies did not indicate that there is no potential conflict of interest of study 
researchers and funders.  
We carried out simple comparisons to assess whether certain study characteristics (above and beyond 
treatment of interest, country and type of cancer) appear to have a bearing on reported cost-
effectiveness values and authors’ conclusions. To disentangle the influence of a particular aspect, one 
would ideally compare studies with similar aims and characteristics which would however differ with 
respect to the aspect of interest. However, the relatively small number of the selected studies and the 
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diversity in type of primary cancer, treatments and methods used limit the comparability between 
studies and the scope for dependable conclusions. With this in mind, we found no discernible 
influences of either the time horizon of the analysis or the analytic approach employed (e.g. trial or 
model-based evaluation) on reported cost per outcome values. For example, in the five studies 
comparing denosumab against ZA in the US [35-37, 39, 40], a longer time horizon corresponded with 
both more and less favourable cost per outcome ratio for the treatment. A similarly picture emerged 
when comparing outcomes from trial-based economic evaluations versus model-based evaluations; 
both favourable and unfavourable cost per outcome values were reported irrespective of the type of 
analysis. Similarly, two [28, 33] of the three studies that adopted a societal perspective as compared 
to narrower (health care system and third-party payer) perspectives reported results which were on 
par with conclusions drawn in the rest of the literature for the particular treatments (i.e. 
bisphosphonates more cost-effective than placebo). The third study that adopted a societal 
perspective compared multiple fraction EBR with single fraction EBR in the Netherlands [38], with the 
authors reporting results comparable to a study investigating the same treatment regimens in the US, 
which, however, adopted a third-party perspective [22]. All in all, our investigation failed to find 
evidence that particular factors or design characteristics appear to have a systematic influence on 
reported cost per outcome values.  
In addition to informing treatment recommendations, an explicit representation of uncertainty is 
useful in determining whether funding and conducting further research would be economically 
worthwhile [55]. Analytic methods such as ‘value of information’ (VoI) and ‘prospective payback of 
research’ are available to provide estimates of the potential value of research and indicate whether 
further evidence should be pursued [56, 57]. The value of, and methodology for, conducting such 
analyses—particularly VoI—is well established [58], with VoI calculations being increasingly 
undertaken in different disease areas, including cancer [59-61]. Despite this, and the fact that such 
calculations require little additional time or inputs  [62-64], none of the reviewed studies undertook 
such work to explore the need for further research, especially around key uncertain parameters such 
as SRE incidence.  
4.3 Strengths and limitations 
The review has a number of strengths. In line with recommendations, we searched key electronic 
bibliographic databases by using combinations of free text and indexing terms. Additional searches 
were carried out on reference lists of known and identified references, including systematic reviews. 
Identified studies were independently assessed by two reviewers for inclusion against a set of 
predetermined criteria. No restrictions were applied on types of economic evaluation or analytic 
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approach used: all types of full economic evaluations, as per the definition by Drummond et al. [45] 
were considered relevant, including both trial and model-based economic evaluation.  
Nonetheless, our review presents certain limitations. First, for pragmatic reasons, only articles 
published in English were included in our review. While excluding articles published in other languages 
poses the risk of missing out important information, research suggests that exclusion of articles in 
languages other than English is unlikely to result in systematic bias [65, 66]. Secondly, our review’s 
focus on full economic evaluations means that studies reporting only costs (such as cost-analyses) 
were not included. While such partial evaluations studies can offer detailed information into the costs 
associated with a treatment, they do not provide information that would allow answering resource 
allocation decisions and, they are, as a result, less valuable for decision making [45]. Lastly, our review 
excluded non-peer-reviewed studies (e.g. internal reports), work not reporting original research (e.g. 
opinion papers) or work published in a restricted format (conference abstracts). While all this 
literature is likely to provide insights into the review question, such studies are of no direct interest as 
far as they do not report complete results of an economic evaluation carried out to assess the value 
of treatments for bone metastases.  
5. Conclusions 
In summary, the reviewed evidence suggests that bisphosphonate treatment is a cost-effective option 
for bone metastases. While denosumab is shown to result is small reductions in SREs and modest gains 
in QoL, there is broad agreement that, due to treatment’s substantial additional costs, the treatment 
is unlikely to represent value for money. Evidence on the economic value of EBR and the 
radiopharmaceutical Sr89 is relatively limited and less conclusive. Sr89 is likely to be a cost-effective 
option, but findings around the most beneficial delivery schedule are equivocal. 
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Table 1. Summary of methods employed in the reviewed studies. 
Study (year) Country 
(perspective) 
Type of economic 
evaluation (analytic 
method employed) 
Time horizon (discounting 
and rate) 
Main cost categories and year of 
valuation 
Measure of benefit 
(instrument) 
Andronis et al. [18], 
James et al. [29] (2016) 
UK (health care 
system) 
 
CUA ( trial-based 
economic evaluation)  
24 months (discounting 
performed at 3.5% per 
year) 
-Treatment-related costs  
-Hospital care cost 
-Primary/community care costs 
Valuation year: 2011/12 
QALY (EQ-5D-3L) 
 
Botteman et al. [19] 
(2006) 
UK (health care 
system) 
 
CUA (model-based 
economic evaluation) 
10 years (discounting 
performed at 3.5% per 
year) 
-Treatment-related costs 
-Hospital care costs 
-Primary/community care costs 
Valuation year: 2005 
QALY (QoL weights taken 
from the literature) 
Botteman et al. [20] 
(2011) 
France, Germany, 
UK (health care 
system) 
 
CUA (model-based 
economic evaluation) 
21 months (discounting 
performed at 5% per year 
for France and Germany, 
3.5% per year for the UK) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2008 
QALY (QoL weights taken 
from the literature) 
 
Carter et al. [21] (2011) France, Germany, 
Portugal, the 
Netherlands 
(third-party 
payer) 
CUA (model-based 
economic evaluation) 
15 months (discounting 
not performed) 
-Treatment-related costs  
-Hospital care cost 
Valuation year: 2011 
- SRE avoided 
-QALY (QoL weights taken 
from the literature) 
 
Collinson et al. [22] 
(2016) 
New Zealand 
(health care 
system) 
CUA (model-based 
economic evaluation) 
Lifetime (discounting 
performed at 3% per year) 
-Treatment-related costs 
-Hospital care cost 
-Primary/community care costs 
-Patient out-of-pocket expenditures 
(travel costs) 
Valuation year: 2011 
QALY (calculated using 
disability weights from 
the Global Burden of 
Disease study [67]) 
De Cock et al. [23] 
(2005) 
UK (health care 
system) 
CUA (model-based 
economic evaluation) 
14.3 months (discounting 
not performed)  
-Treatment-related costs  
-Hospital care costs 
Valuation year: 2003 
QALY (QoL weights taken 
from the literature)  
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De Cock et al. [24] 
(2005) 
UK (health care 
system) 
CUA (model-based 
economic evaluation) 
14.3 months (discounting 
not performed)  
- Treatment-related costs  
- Hospital care costs 
Valuation year not reported 
QALY (QoL weights taken 
from the literature)  
Dranitsaris and Hsu 
[25] (1999) 
Canada (health 
care system) 
CUA (model-based 
economic evaluation) 
12 months (discounting 
not applicable) 
- Treatment-related costs 
- Hospital and specialist care costs 
Valuation year: 1999 
QALY (derived through a 
TTO exercise) 
Ford et al. [26] (2013) UK (health care 
system) 
CUA (model-based 
economic evaluation) 
10 years (discounting 
performed at 3.5% per 
year) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2010 
- QALY (QoL weights 
taken from drug 
manufacturer’s evidence 
submission to NICE) 
- SRE avoided 
Gessner et al. [27] 
(2000) 
Switzerland 
(third-party 
payer) 
CCA (trial-based 
economic evaluation) 
10.5 months (discounting 
not applicable) 
- Treatment-related costs 
- Hospital and specialist care costs 
Valuation year: 1995 
Linear analogue scale 
measuring pain levels 
Hillner et al. [28] (2000) US (societal) CEA, CUA (model-
based economic 
evaluation) 
24 months (discounting 
not performed) 
- Treatment-related costs 
- Hospital care costs 
- Primary/community care costs 
- Productivity cost of patients’ 
companion 
Valuation year not reported 
- SRE avoided 
- QALY (instrument not 
reported) 
Joshi et al. [30] (2011) France, Germany, 
Netherlands, 
Portugal, UK 
(health care 
system)  
CUA (model-based 
economic evaluation) 
Unclear (discounting not 
performed) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2007/08 
QALY (QoL weights taken 
from the literature) 
Konski [31] (2004) US (third-party 
payer) 
CUA (model-based 
economic evaluation) 
24 months (discounting 
not performed) 
-Treatment-related costs 
-Hospital care costs 
Valuation year not reported 
QALY (QoL weights taken 
from the literature) 
McEwan et al. [32] 
(1994) 
Canada (not 
reported) 
 
CEA (trial-based 
economic evaluation) 
Lifetime (discounting not 
performed) 
-Treatment-related costs 
-Hospital care costs  
Length of survival 
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Valuation year: 1989 
Reed et al. [33] (2004) US (societal)  CEA, CUA (trial-based 
economic evaluation) 
15 months (discounting 
not performed) 
 
-Treatment-related costs  
-Hospital care cost 
-Primary/community care costs 
Valuation year: 2000 
- SAE avoided 
- QALY (EQ-5D-3L) 
Ross et al. [34] (2004) UK (health care 
perspective) 
 
CEA (model-based 
economic evaluation) 
4 years (discounting 
performed for the 
assessment of treatments 
for skeletal morbidity: 6% 
per year for costs, 1% per 
year for outcomes (SREs). 
- Treatment-related costs 
- Hospital care costs 
- Primary and community care costs 
(only for the assessment of skeletal 
morbidity) 
Valuation year: 2000/2001 
- LYG 
- SRE avoided 
Snedecor et al. [35] 
(2012) 
US (third-party 
payer) 
 
CUA (model-based 
economic evaluation) 
27 months (discounting 
performed at 3% per year) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2010 
QALY (QoL weights taken 
from the literature) 
Snedecor et al. [36] 
(2013) 
US (third-party 
payer) 
 
CUA (model-based 
economic evaluation) 
27 months (discounting 
performed at 3% per year) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2010 
QALY (QoL weights taken 
from the literature) 
Stopeck et al. [37] 
(2012) 
US (third-party 
payer) 
CEA, CUA (model-
based economic 
evaluation) 
Lifetime (discounting 
performed at 3% per year) 
 
-Treatment-related costs 
-Hospital care costs 
Valuation year: 2011 
-SRE avoided 
-QALY (various including 
EQ-5D-3L and TTO 
exercises) 
Van den Hout et al. [38] 
(2003) 
UK (societal) CUA (trial-based 
economic evaluation) 
12 months for outcomes 
(discounting performed at 
3% per year) 
- Treatment-related costs 
- Hospital and specialist care costs 
- Primary/community care costs 
- Patient payments 
Valuation year: 2002 
QALY (EQ-5D-3L) 
Xie et al. [39] (2012) US (third-party 
payer) 
 
CEA (model-based 
economic evaluation) 
12 months (discounting 
not applicable) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2011 
- SRE avoided 
- Pathologic fracture 
avoided 
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Xie et al. [40] (2011) US (third-party 
payer) 
 
CEA (model-based 
economic evaluation) 
12 months (discounting 
performed at 3% per year)  
- Treatment-related costs 
- Hospital care costs 
- Terminal care costs 
Valuation year: 2012 
SRE avoided 
Yfantopoulos et al. [41] 
(2013) 
Greece (health 
care system) 
CUA (model-based 
economic evaluation) 
14.5 months for breast 
cancer; 22.5 months for 
prostate cancer 
(discounting not 
performed); 9 months for 
other solid tumours 
(discounting not 
applicable) 
- Treatment-related costs 
- Hospital care costs 
Valuation year: 2013 
-QALY (QoL weights taken 
from the literature) 
CBA: cost-benefit analysis; CCA: cost consequences analysis; CEA: cost-effectiveness analysis; CUA: cost-utility analysis; EQ-5D: EuroQol 5D; LYG: life-year gained; NICE: 
National Institute for Health and Care Excellence; SRE: skeletal-related event; QALY: quality-adjusted life year; QoL: quality of life; TTO: time trade-off elicitation method.  
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Table 2. Summary of findings reported in the reviewed studies.  
Study (year) Type(s) of primary 
cancer investigated 
Intervention(s) and 
comparator(s) 
Main findings 
Andronis et al. [18], 
James et al. [29] 
(2016) 
Prostate 
 
Interventions: ZA; Sr89 
Comparators: No ZA; No Sr89 
 
-ICER (ZA vs. no ZA): £8,005 per QALY  
-ZA is less costly and more effective than no ZA if the price of generic ZA is less than 
£31. 
-ICER (Sr89 vs. no Sr89): £16,884 per QALY gained. 
Botteman et al. [19] 
(2006) 
Breast Interventions: ibandronate (oral 
or intravenous); ZA; 
pamidronate; clodronate (oral). 
Comparator(s): placebo 
-ZA vs no therapy: cost savings of £2,267 and 0.205 additional QALYs.  
-Oral ibandronate vs. placebo: cost savings of £2,114 and 0.185 additional QALYs. 
- ICER (pamidronate vs. placebo): £584 per QALY gained.  
- ICER (intravenous ibandronate vs. placebo): £2,370 per QALY gained. 
Botteman et al. [20] 
(2011) 
Renal cancer Intervention: ZA 
Comparator: placebo 
- ZA vs placebo: cost savings and additional SREs avoided in all countries 
considered. 
- ZA vs placebo: cost savings and additional QALYs in all countries considered. 
Carter et al. [21] 
(2011) 
Prostate 
 
 
Intervention: ZA 
Comparator(s): placebo 
 
 
- ICER (France, ZA vs placebo): €36,007 per QALY gained. 
-ICER (Germany, ZA vs placebo): €23,582 per QALY gained. 
-ICER (Portugal, ZA vs placebo): €8,655 per QALY gained. 
-ICER (Netherlands, ZA vs placebo): €2,430 per QALY gained. 
Collinson et al. [22] 
(2016) 
Breast, prostate, lung Intervention: single-fraction EBR 
Comparators: multi-fraction EBR; 
analgesia (in a secondary 
analysis) 
Single-fraction EBR was less costly and more effective than multi-fraction EBR. 
De Cock et al. [23] 
(2005) 
Breast (patients 
receiving oral 
hormonal therapy) 
Intervention(s): pamidronate 
(oral) 
Comparator(s): ZA (intravenous); 
pamidronate (generic, 
intravenous). 
 
-Oral ibadronate vs. intravenous ZA: cost savings of £307and 0.018 additional 
QALYs. 
-Oral ibadronate vs. intravenous generic pamidronate: cost savings of £158 and 
0.019 additional QALYs. 
De Cock et al. [24] 
(2005) 
Breast (patients 
receiving 
chemotherapy) 
Intervention: pamidronate (oral) 
Comparators: ZA (intravenous); 
pamidronate (generic, 
intravenous) 
-Oral ibadronate vs. intravenous ZA: cost savings of £386 and 0.019 additional 
QALYs. 
-Oral ibadronate vs. intravenous generic pamidronate: cost savings of £224 and 
0.02 additional QALYs. 
Dranitsaris and Hsu 
[25] (1999) 
Breast 
 
Intervention: pamidronate 
Comparator: placebo 
ICER (pamidronate vs. placebo): CAN $18,700 per QALY gained.   
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Ford et al. [26] 
(2013) 
Breast, prostate, 
lung, other solid 
tumours 
Intervention: denosumab 
Comparator: ZA 
 
Breast cancer:  
- ICER (denosumab vs ZA, without PAS): £245,264 per QALY gained. 
- Denosumab vs ZA (with PAS): cost savings and additional QALYs. 
 
Prostate cancer: 
- ICER (denosumab vs ZA, without PAS): £111,603 per QALY gained. 
- Denosumab vs ZA (with PAS): cost savings and additional QALYs. 
 
Lung cancer: 
- ICER (denosumab vs ZA, without PAS): £110,671 per QALY gained. 
- ICER (denosumab vs ZA, with PAS): £12,743 per QALY gained.  
 
Other solid tumours: 
- ICER (denosumab vs ZA, without PAS): £139,739 per QALY gained.  
- ICER (denosumab vs ZA, with PAS): £9,004 per QALY gained. 
Gessner et al. [27] 
(2000) 
Breast, multiple 
myeloma, other 
cancer types 
 
Intervention(s): pamidronate 
60mg  
Comparator(s): pamidronate 
90mg  
- Average total cost (for both treatments): ECU 12,060 +/- 4,380 
- Change in pain intensity compared to baseline value (pamidronate 60mg): -36%. 
- Reduction in pain intensity compared to baseline value (pamidronate 90mg): -
15%.  
Hillner et al. [28] 
(2000) 
Breast Intervention: pamidronate (given 
with either hormonal systemic 
therapy or chemotherapy) 
Comparator: placebo 
-ICER (pamidronate plus chemotherapy vs. placebo): US $3,940 per SRE avoided. 
- ICER (pamidronate plus chemotherapy vs. placebo): US $108,200 per QALY 
gained. 
-ICER (pamidronate plus hormonal systemic therapy vs. placebo): US $7,685 per 
SRE avoided. 
- ICER (pamidronate plus hormonal systemic therapy vs. placebo): US $305,300 per 
QALY gained.  
Joshi et al. [30] 
(2011) 
Lung Intervention: ZA 
Comparator: placebo 
 
- ZA vs placebo (Germany, UK and Portugal): costs savings and additional QALYs. 
- ICER (ZA vs placebo; France): €786 per QALY gained.  
-ICER (ZA vs placebo; Netherlands): €8278 per QALY gained.  
Konski [31] (2004) Prostate 
 
Interventions: chemotherapy 
only (mitoxantrone plus 
prednisolone); single-fraction 
EBR; multi-fraction EBR. 
Comparator: BSC (pain 
medications only) 
-ICER (single-fraction EBR vs. BSC): US $6857 per QALY gained.  
-ICER (multiple-fraction EBR vs. BSC): US $36,000 per QALY gained.  
-ICER (single-fraction EBR vs. multiple fraction EBR) (calculated)a: US $8,667 per 
QALY gained.  
-Chemotherapy is more costly and less effective than all other options.  
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McEwan et al. [32] 
(1994) 
Prostate Intervention: Sr89 (Metastron®) 
Comparator: placebo 
-Cost per week survival (Metastron® vs. placebo): cost savings of CAN $209. 
Reed et al. [33] 
(2004) 
Prostate 
 
Intervention: ZA 
Comparator: placebo 
-ICER (ZA vs placebo): US $12,300 per SRE avoided. 
-ICER (ZA vs placebo): US $51,400 per additional patient free of SRE. 
-ICER (ZA vs placebo): US $159,200 per QALY gained. 
Ross et al. [34] 
(2004) 
Breast, multiple 
myeloma 
Intervention(s): pamidronate 
(30mg, 60mg and 90mg); 
clodronate (1500mg); ZA (4mg 
and 8mg); ibandronate (2mg, 
4mg, 6mg) 
Comparator(s): no 
bisphosphonate treatment 
 
 
Breast cancer: 
- ICER (treatment of hypecalcaemia, ZA 8mg vs no bisphosphonate treatment): 
£17,100 per LYG 
- ICER (prevention of skeletal morbidity, ZA vs no bisphosphonate therapy): £250 
per SRE avoided.  
 
Multiple myeloma:  
- ICER (prevention of skeletal morbidity, ZA vs no bisphosphonate therapy): £1,497 
per SRE avoided.   
Snedecor et al. [35] 
(2012) 
Breast Intervention: denosumab 
Comparator: ZA 
-ICER (denosumab vs. ZA): US $697,499 per QALY gained. 
Snedecor et al. [36] 
(2013) 
Prostate Intervention: denosumab 
Comparator(s): ZA 
-ICER (denosumab vs. ZA): US $1,058,741 per QALY gained.  
Stopeck et al. [37] 
(2012) 
Prostate, breast, lung 
 
Intervention: denosumab 
Comparator: ZA 
 
Prostate cancer 
-ICER (denosumab vs ZA): US $49,405 per QALY gained.  
-ICER US $8,567 per SRE avoided. 
 
Breast cancer 
-ICER (denosumab vs ZA): US $78,915 per QALY gained. 
-ICER (denosumab vs ZA): US $13,557 per SRE avoided. 
 
Lung cancer 
- ICER (denosumab vs ZA): US $67,931 per QALY gained. 
- ICER (denosumab vs ZA): US $13,557 per SRE avoided. 
Van den Hout et al. 
[38] (2003) 
Breast, lung, 
prostate, other 
 
Intervention: single-fraction EBR 
Comparator(s): multiple-fraction 
EBR (six fractions) 
Single-fraction EBR was less costly and more effective than multi-fraction EBR. 
Xie et al. [39] (2012) Breast Intervention: denosumab 
Comparator: ZA 
-ICER (denosumab vs. ZA): US $114,628 per SRE avoided. 
-ICER (denosumab vs. ZA): US $290,136 per pathological fracture avoided. 
Xie et al. [40] (2011) Prostate Intervention: denosumab 
Comparator: ZA 
-ICER (denosumab vs. ZA, 12 months): US $71,027 per SRE avoided. 
-ICER (denosumab vs. ZA, 36 months): US $51,319 per SRE avoided. 
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Yfantopoulos et al. 
[41] (2013) 
-Breast, prostate, 
other 
solid tumours (not 
specified) 
Intervention: denosumab 
Comparator: ZA 
Breast cancer 
-ICER (denosumab vs ZA): €56,818 per QALY gained. 
 
Prostate cancer: 
-ICER (denosumab vs ZA): €61,296 per QALY gained. 
 
Other solid tumours 
- ICER (denosumab vs ZA): €80,830 per QALY gained. 
a Calculated on the basis of information given in the article. 
BSC: best supportive care; EBR: external beam radiotherapy; ECU: European Currency Unit; ICER: incremental cost effectiveness ratio; LYG: life-year gained; NICE: 
National Institute for Health and Care Excellence; OST: other solid tumours; PAS: patient-access scheme; QALY: quality-adjusted life year; Sr89: strontium-89; TTO: time 
trade-Off elicitation method; ZA: zoledronic acid.  
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Table 3. Answers to the Consensus on Health Economic Criteria (CHEC) checklist [17] 
Study 
Item 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Andronis et al. [18] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N 
Botteman et al. [19] Y Y Y Y Y Y Y Y Y Y Y Y N Y Y N N N* N 
Botteman et al. [20] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N* N 
Carter et al. [21] Y Y Y Y Y Y Y Y Y Y Y Y Y U Y Y Y N* N 
Collinson et al. [22] Y Y Y Y Y U Y Y Y Y Y Y Y Y Y Y Y N* N 
De Cock et al. [23] Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y N N* N 
De Cock et al. [24] Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y N N 
Dranitsaris & Hsu [25] Y Y Y Y Y Y Y Y Y Y Y Y Y N/A Y Y N N* N 
Ford et al. [26] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N* N 
Gessner et al. [27] Y Y Y U N Y U Y Y Y Y Y N N/A U Y N N* N 
Hillner et al. [28] Y Y Y Y Y Y Y Y U Y Y U Y N Y Y N Y N 
James et al. [29] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N* N 
Joshi et al. [30] Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y N* N 
Konski [31] Y Y Y Y Y Y U Y U U U Y Y N Y Y N N Y 
McEwan et al. [32] Y Y Y Y Y U N Y Y N Y Y Y N N Y N Y N 
Reed et al. [33] Y Y Y Y Y Y N Y Y Y Y Y Y U U Y Y N* N 
Ross et al. [34] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Snedecor et al. [35] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N* N 
Snedecor et al. [36] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N* N 
Stopeck et al. [37] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N* N 
van den Hout et al. [38] Y Y Y U U Y U Y Y Y Y Y Y Y N Y N Y N 
Xie et al. [40] Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N* N 
Xie et al. [39] Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y N* N 
Yfantopoulos et al. [41] Y Y Y Y Y Y Y Y Y Y Y Y Y N N Y N N* N 
Y: Yes; N: No; U: Unclear; N/A: Not applicable.  
* Funding sources and potential conflicts of interests are acknowledged.  
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Item 1: Is the study population clearly described? Item 2: Are competing alternatives clearly described? Item 3: Is a well-defined research question posed in answerable 
form? Item 4: Is the economic study design appropriate to the stated objective? Item 5: Is the chosen time horizon appropriate to include relevant costs and consequences? 
Item 6: Is the actual perspective chosen appropriate? Item 7: Are all important and relevant costs for each alternative identified? Item 8: Are all costs measured 
appropriately in physical units? Item 9: Are costs valued appropriately? Item 10: Are all important and relevant outcomes for each alternative identified? Item 11: Are all 
outcomes measured appropriately? Item 12: Are outcomes valued appropriately? Item 13: Is an incremental analysis of costs and outcomes of alternatives performed? 
Item 14: Are all future costs and outcomes discounted appropriately? Item 15: Are all important variables, whose values are uncertain, appropriately subjected to sensitivity 
analysis? Item 16: Do the conclusions follow from the data reported? Item 17: Does the study discuss the generalizability of the results to other settings and patient/ client 
groups? Item 18: Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? Item 19: Are ethical and distributional issues 
discussed appropriately? 
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Figure 1. PRISMA flowchart 
Records identified through 
database searching 
(n=3467) 
 
Breast cancer (n=1160) 
Lung cancer (n=725) 
Renal cancer (n=294) 
Prostate cancer (n=1167) 
Thyroid cancer (n=121) 
 
 
Additional records identified 
through other sources 
(n= 12) 
Unique records screened 
(n =   2495) 
Records excluded on the 
basis of title and abstract 
(n = 2414) 
Full-text articles assessed 
for eligibility 
(n = 81) 
Full-text articles excluded  
(n=57)  
 
 
No full text available (e.g. 
conference abstracts): 18 
Not a full economic evaluation: 17  
Assessed treatment not targeting 
bone metastases: 10 
Not original research (e.g. letters, 
opinion articles): 8 
Irrelevant intervention (e.g. 
diagnosis, staging etc): 3  
Not in English: 1 
 
 
Studies included the 
systematic review  
(n=24) 
 42 
 
 
Figure 2. Identified studies by type of primary cancer investigated. 
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Figure 3. Identified studies by publication year. 
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QALY and SRE 
(n=3) 
SRE and other 
measures 
(n=2) 
SRE avoided 
(n=6) 
QALY 
(n=17) 
Other measures 
(n=4) 
(Pain intensity (n=1), duration of 
normocalcaemia (n = 1), pathological 
fractures avoided 
 (n= 1), length of survival (n= 1)) 
Figure 4. Identified studies by measures of outcomes. 
